Literature DB >> 26233232

Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme.

R Cerqua1, S Balestrini2, C Perozzi1, V Cameriere1, S Renzi1, G Lagalla1, G Mancini3, M Montanari3, P Leoni3, M Scerrati4, M Iacoangeli4, M Silvestrini1, S Luzzi1, L Provinciali1.   

Abstract

Glioblastoma multiforme (GBM) and primary central nervous system lymphoma (PCNSL) are malignant cerebral neoplasms associated with poor prognosis. Early diagnosis and subsequent planning of adequate treatment strategy are relevant to improve survival and reduce neurological deficit. Two groups of patients affected by GBM and PCNSL were compared to identify: (1) factors influencing the time necessary to obtain a correct diagnosis; (2) the influence of the interval time from clinical onset to diagnosis on the prognosis. Fifty-six patients (28 PCNSL and 28 GBM, 23 females and 33 males) referred to the same hospital setting were retrospectively evaluated. The mean age at diagnosis was 61 years. The two groups were comparable in terms of age, sex, clinical symptoms at onset and performance status. There was no relevant difference in time span from clinical onset to first neuroimaging examination, while time span from first neuroimaging to final morphological diagnosis was much longer in PCNSL patients (p = 0.008). Multivariate Cox regression analysis, including both PCNSL and GBM cases, showed a significant association of the overall survival with: time to diagnosis (HR 0.06), age at onset (HR 1.04). Our results show a significant diagnostic delay in PCNSL cases. Age at onset of disease and time to diagnosis emerge as clinical factors affecting overall survival in both groups. Stereotactic-guided biopsy should be chosen as routine method to early diagnose PCNSL. The clinical relevance of early diagnosis in GBM and PCNSL needs to be emphasized to maximize the overall survival in both neoplasms.

Entities:  

Keywords:  Diagnostic delay; Glioblastoma multiforme; Overall survival; Primary central nervous lymphoma

Mesh:

Substances:

Year:  2015        PMID: 26233232     DOI: 10.1007/s10072-015-2353-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  40 in total

1.  Preoperative blood oxygen level-dependent functional magnetic resonance imaging in patients with primary brain tumors: clinical application and outcome.

Authors:  Asta Håberg; Kjell Arne Kvistad; Geirmund Unsgård; Olav Haraldseth
Journal:  Neurosurgery       Date:  2004-04       Impact factor: 4.654

2.  Non-invasive in vivo assessment of IDH1 mutational status in glioma.

Authors:  Myriam M Chaumeil; Peder E Z Larson; Hikari A I Yoshihara; Olivia M Danforth; Daniel B Vigneron; Sarah J Nelson; Russell O Pieper; Joanna J Phillips; Sabrina M Ronen
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

3.  Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.

Authors:  Amy S Darefsky; Joseph T King; Robert Dubrow
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

4.  Surgery for primary CNS lymphoma? Challenging a paradigm.

Authors:  Michael Weller; Peter Martus; Patrick Roth; Eckhard Thiel; Agnieszka Korfel
Journal:  Neuro Oncol       Date:  2012-09-14       Impact factor: 12.300

Review 5.  Management of malignant gliomas and primary CNS lymphoma: standard of care and future directions.

Authors:  Myrna R Rosenfeld; Amy A Pruitt
Journal:  Continuum (Minneap Minn)       Date:  2012-04

6.  Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.

Authors:  Annika Juergens; Hendrik Pels; Sabine Rogowski; Klaus Fliessbach; Axel Glasmacher; Andreas Engert; Marcel Reiser; Volker Diehl; Marlies Vogt-Schaden; Gerlinde Egerer; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Udo Bode; Ulrich Herrlinger; Michael Linnebank; Martina Deckert; Rolf Fimmers; Ingo G H Schmidt-Wolf; Uwe Schlegel
Journal:  Ann Neurol       Date:  2010-02       Impact factor: 10.422

Review 7.  Genetics of glioblastoma: a window into its imaging and histopathologic variability.

Authors:  Clifford J Belden; Pablo A Valdes; Cong Ran; David A Pastel; Brent T Harris; Camilo E Fadul; Mark A Israel; Keith Paulsen; David W Roberts
Journal:  Radiographics       Date:  2011-10       Impact factor: 5.333

8.  Is a "vanishing tumor" always a lymphoma?

Authors:  J E C Bromberg; M D Siemers; M J B Taphoorn
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

9.  Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.

Authors:  Francesc Graus; Jordi Bruna; Javier Pardo; Domingo Escudero; Dolores Vilas; Inés Barceló; Marta Brell; Carmen Pascual; José A Crespo; Elena Erro; Juan C García-Romero; Jordi Estela; Juan Martino; Almudena García-Castaño; Elena Mata; Manuela Lema; Miguel Gelabert; Rafel Fuentes; Pedro Pérez; Arancha Manzano; Jesús Aguas; Antonio Belenguer; Ana Simón; Iván Henríquez; Mauricio Murcia; Rosa Vivanco; Iñigo Rojas-Marcos; David Muñoz-Carmona; Inmaculada Navas; Pablo de Andrés; Gemma Mas; Miguel Gil; Eugènia Verger
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300

10.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

Authors:  Andrés J M Ferreri; Jean-Yves Blay; Michele Reni; Felice Pasini; Michele Spina; Achille Ambrosetti; Antonello Calderoni; Andrea Rossi; Vittorio Vavassori; Annarita Conconi; Liliana Devizzi; Françoise Berger; Maurilio Ponzoni; Bettina Borisch; Marianne Tinguely; Michele Cerati; Mario Milani; Enrico Orvieto; Juvenal Sanchez; Christine Chevreau; Stefania Dell'Oro; Emanuele Zucca; Franco Cavalli
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

View more
  6 in total

1.  Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.

Authors:  R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna
Journal:  J Neurooncol       Date:  2020-06-10       Impact factor: 4.130

2.  Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.

Authors:  Daniel Paech; Constantin Dreher; Sebastian Regnery; Jan-Eric Meissner; Steffen Goerke; Johannes Windschuh; Johanna Oberhollenzer; Miriam Schultheiss; Katerina Deike-Hofmann; Sebastian Bickelhaupt; Alexander Radbruch; Moritz Zaiss; Andreas Unterberg; Wolfgang Wick; Martin Bendszus; Peter Bachert; Mark E Ladd; Heinz-Peter Schlemmer
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

3.  Microscopic biopsy after unsuccessful endoscopic biopsy for primary central nervous system lymphoma of the corpus callosum: A case report.

Authors:  Tokunori Kanazawa; Kosuke Karatsu; Takumi Kuramae; Masayuki Ishihara
Journal:  Ann Med Surg (Lond)       Date:  2021-08-24

4.  Symptoms in primary care with time to diagnosis of brain tumours.

Authors:  Mio Ozawa; Paul M Brennan; Karolis Zienius; Kathreena M Kurian; William Hollingworth; David Weller; Willie Hamilton; Robin Grant; Yoav Ben-Shlomo
Journal:  Fam Pract       Date:  2018-09-18       Impact factor: 2.267

Review 5.  An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients.

Authors:  Florian Scheichel; Daniel Pinggera; Branko Popadic; Camillo Sherif; Franz Marhold; Christian Franz Freyschlag
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

Review 6.  Diagnosis of primary central nervous system lymphoma: a systematic review of the utility of CSF screening and the role of early brain biopsy.

Authors:  Alexis A Morell; Ashish H Shah; Claudio Cavallo; Daniel G Eichberg; Christopher A Sarkiss; Ronald Benveniste; Michael E Ivan; Ricardo J Komotar
Journal:  Neurooncol Pract       Date:  2019-04-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.